ClinicalTrials.gg
CompletedNCT02574845Updated Nov 7, 2023Results posted

DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)

A Phase 1 interventional study of Rosuvastatin and Metformin HCl in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The primary objective of this trial is to investigate the relative bioavailability of rosuvastatin when given alone (Reference treatment, R) compared to when given together with one of the three different doses of metformin (10 mg, Test treatment 1 (T1); 50 mg (T2); 500 mg (T3)) or one of the two doses of furosemide (1 mg (T4); 5 mg (T5)).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the investigators assessment, based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead , and clinical laboratory tests
  2. Age of 18 to 55 years (incl.)
  3. of 18.5 to 29.9 kg/m2 (incl.)
  4. Signed and dated written prior to admission to the study in accordance with GCP and local legislation

Exclusion criteria

Exclusion criteria:

  1. Any finding in the medical examination (including BP, PR or ) is deviating from normal and judged as by the investigator
  2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  4. Any evidence of a concomitant disease judged as clinically relevant by the investigator
  5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  6. Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  8. History of relevant orthostatic hypotension, fainting spells, or blackouts
  9. Chronic or relevant acute infections
  10. History of relevant allergy or (including allergy to the trial medication or its )
  11. Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10 half-lives of the respective drug prior to administration of trial medication
  12. Within 10 days prior to administration of trial medication, use of drugs that might reasonably influence the results of the trial
  13. Participation in another trial where an drug has been administered within 60 days prior to planned administration of trial medication
  14. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  15. Inability to refrain from smoking on specified trial days
  16. Alcohol abuse (consumption of more than 30 g per day)
  17. Drug abuse or positive drug screening
  18. Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  19. Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  20. Inability to comply with dietary regimen of trial site
  21. Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study

    In addition, the following trial-specific exclusion criteria apply:

  22. Myopathy
  23. Hereditary galactose or fructose intolerance, lactase deficiency, or glucose-galactose malabsorption
  24. Allergy or hypersensitivity against sulfonamides
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    R (Reference) Rosuvastatin

    1film-coated tablet as single dose, fasted

    Drug: Rosuvastatin

  • Experimental
    T1 (Test 1) Rosuvastatin + Metformin HCl

    Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (10 mg) as single dose, fasted

    Drug: Rosuvastatin · Drug: Metformin HCl

  • Experimental
    T2 (Test 2) Rosuvastatin + Metformin HCl

    Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (50 mg) as single dose, fasted

    Drug: Rosuvastatin · Drug: Metformin HCl

  • Experimental
    T3 (Test 3) Rosuvastatin + Metformin HCl

    Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (500 mg) as single dose, fasted

    Drug: Rosuvastatin · Drug: Metformin HCl

  • Experimental
    T4 (Test 4) Rosuvastatin + Furosemide

    Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (1 mg) as single dose, fasted

    Drug: Rosuvastatin · Drug: Furosemide

  • Experimental
    T5 (Test 5) Rosuvastatin + Furosemide

    Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (5 mg) as single dose, fasted

    Drug: Rosuvastatin · Drug: Furosemide

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve of Rosuvastatin From 0 to the Last Quantifiable Data Point (AUC0-tz)

    This outcome measure presents the area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).

    Time frame: Blood sampling within 3 hours (h) prior to the study drug administration, at the time of administration (0:00) and 30 minutes, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 11h, 12h, 24h, 34h, and 48h thereafter.

  2. Maximum Concentration of Rosuvastatin (Cmax)

    This outcome measure presents the maximum measured concentration of rosuvastatin in plasma (Cmax).

    Time frame: Blood sampling within 3 hours (h) prior to the study drug administration, at the time of administration (0:00) and 30 minutes, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 11h, 12h, 24h, 34h, and 48h thereafter.

Secondary outcomes

  1. Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC0-∞)

    This outcome measure presents area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).

    Time frame: Blood sampling within 3 hours (h) prior to the study drug administration, at the time of administration (0:00) and 30 minutes, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 11h, 12h, 24h, 34h, and 48h thereafter.

07

Results

Posted Feb 13, 2017

Participant flow

All subjects were screened for eligibility to participate in the study. No run-in or wash-out period was conducted, since the trial was conducted in healthy subjects, that were not expected to take medications regularly. Actual number of subjects enrolled in fact represents randomized subjects due to the study set up.

Participant flow — Overall Study
MilestoneTreatment (T) 1-T3-Reference (REF)-T5-T2-T4T2-REF-T4-T1-T5-T3T3-T5-T1-T4-REF-T2T4-T2-T5-REF-T3-T1T5-T4-T3-T2-T1-REFREF-T1-T2-T3-T4-T5
Started333333
Received t1323322
Received t2333323
Received t3223323
Received t4323322
Received t5323332
Received r323323
Completed323322
Not completed010011
Withdrew: Consent withdrawn further participation000010
Withdrew: Adverse event010001

Outcome measures

PrimaryArea Under the Curve of Rosuvastatin From 0 to the Last Quantifiable Data Point (AUC0-tz)

This outcome measure presents the area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).

Time frame:
Blood sampling within 3 hours (h) prior to the study drug administration, at the time of administration (0:00) and 30 minutes, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 11h, 12h, 24h, 34h, and 48h thereafter.
Reported as:
Geometric mean · nanomol (nmol) * hour (h) / Litre (L)
Area Under the Curve of Rosuvastatin From 0 to the Last Quantifiable Data Point (AUC0-tz)
nanomol (nmol) * hour (h) / Litre (L)REF AloneTreatment 1Treatment 2Treatment 3Treatment 4Treatment 5
Area Under the Curve of Rosuvastatin From 0 to the Last Quantifiable Data Point (AUC0-tz)81.5 ± 50.987.8 ± 54.588.7 ± 62.4126 ± 66.791.5 ± 55.497.2 ± 52.7
Statistical analysis
  • REF Alone vs Treatment 1 · ANOVA · Adjusted geometric mean ratio t1/ref (%): 101.95 · 90% CI 89.49 to 116.15Analysis of variance (ANOVA) model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 2 · ANOVA · Adjusted geometric mean ratio t2/ref (%): 106.09 · 90% CI 96.12 to 117.11ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 3 · ANOVA · Adjusted geometric mean ratio t3/ref (%): 152.18 · 90% CI 135.12 to 171.41ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 4 · ANOVA · Adjusted geometric mean ratio t4/ref (%): 106.97 · 90% CI 94.34 to 121.30ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 5 · ANOVA · Adjusted geometric mean ratio t5/ref (%): 115.92 · 90% CI 101.93 to 131.82ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
PrimaryMaximum Concentration of Rosuvastatin (Cmax)

This outcome measure presents the maximum measured concentration of rosuvastatin in plasma (Cmax).

Time frame:
Blood sampling within 3 hours (h) prior to the study drug administration, at the time of administration (0:00) and 30 minutes, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 11h, 12h, 24h, 34h, and 48h thereafter.
Reported as:
Geometric mean · nmol/L
Maximum Concentration of Rosuvastatin (Cmax)
nmol/LREF AloneTreatment 1Treatment 2Treatment 3Treatment 4Treatment 5
Maximum Concentration of Rosuvastatin (Cmax)9.04 ± 52.49.59 ± 60.59.94 ± 69.414.0 ± 71.29.90 ± 62.010.8 ± 62.7
Statistical analysis
  • REF Alone vs Treatment 1 · ANOVA · Adjusted geometric mean ratio t1/ref (%): 102.47 · 90% CI 87.19 to 120.42ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 2 · ANOVA · Adjusted geometric mean ratio t2/ref (%): 106.98 · 90% CI 92.54 to 123.69ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 3 · ANOVA · Adjusted geometric mean ratio t3/ref (%): 154.07 · 90% CI 131.70 to 180.24ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 4 · ANOVA · Adjusted geometric mean ratio t4/ref (%): 106.81 · 90% CI 91.78 to 124.30ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 5 · ANOVA · Adjusted geometric mean ratio t5/ref (%): 117.98 · 90% CI 98.27 to 141.65ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
SecondaryArea Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC0-∞)

This outcome measure presents area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).

Time frame:
Blood sampling within 3 hours (h) prior to the study drug administration, at the time of administration (0:00) and 30 minutes, 1h, 1:30h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 11h, 12h, 24h, 34h, and 48h thereafter.
Reported as:
Geometric mean · nmol*h/L
Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC0-∞)
nmol*h/LREF AloneTreatment 1Treatment 2Treatment 3Treatment 4Treatment 5
Area Under the Curve of Rosuvastatin From 0 Extrapolated to Infinity (AUC0-∞)99.7 ± 39.0105 ± 48.0102 ± 55.0149 ± 49.8108 ± 47.9115 ± 42.0
Statistical analysis
  • REF Alone vs Treatment 1 · ANOVA · Adjusted geometric mean ratio t1/ref (%): 101.22 · 90% CI 89.23 to 114.82ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 2 · ANOVA · Adjusted geometric mean ratio t2/ref (%): 107.26 · 90% CI 97.65 to 117.81ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 3 · ANOVA · Adjusted geometric mean ratio t3/ref (%): 146.45 · 90% CI 135.21 to 158.62ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 4 · ANOVA · Adjusted geometric mean ratio t4/ref (%): 105.63 · 90% CI 92.20 to 121.00ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.
  • REF Alone vs Treatment 5 · ANOVA · Adjusted geometric mean ratio t5/ref (%): 118.10 · 90% CI 106.75 to 130.67ANOVA model on the logarithmic scale including the effects: 'sequence', 'subjects within sequence', 'period' and 'treatment'.

Adverse events

Collected over From the first administration of study medication to the end of the 4 day residual effect period (96 hours after each administration of study medication) up to 24 days in total.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
REF Alone—0/16 (0%)4/16 (25%)
Treatment 1—0/15 (0%)4/15 (26.7%)
Treatment 2—0/17 (0%)2/17 (11.8%)
Treatment 3—0/15 (0%)2/15 (13.3%)
Treatment 4—0/15 (0%)3/15 (20%)
Treatment 5—0/16 (0%)2/16 (12.5%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventREF AloneTreatment 1Treatment 2Treatment 3Treatment 4Treatment 5
ToothacheGastrointestinal disorders1/160/150/170/151/150/16
NasopharyngitisInfections and infestations0/160/150/171/150/151/16
RhinitisInfections and infestations0/161/150/170/151/151/16
ContusionInjury, poisoning and procedural complications0/161/150/170/150/150/16
Procedural painInjury, poisoning and procedural complications0/160/150/170/151/150/16
ArthralgiaMusculoskeletal and connective tissue disorders0/161/150/170/150/150/16
MyalgiaMusculoskeletal and connective tissue disorders0/161/150/170/150/150/16
HeadacheNervous system disorders1/161/151/171/151/150/16
ParaesthesiaNervous system disorders1/160/150/170/150/150/16
HaematomaVascular disorders1/160/150/170/150/150/16

Baseline characteristics

The randomised set (RS) includes all randomised subjects, whether treated or not.

Age, Continuous
Age, Continuous(years)Treatment (T) 1-T3-Reference (REF)-T5-T2-T4T2-REF-T4-T1-T5-T3T3-T5-T1-T4-REF-T2T4-T2-T5-REF-T3-T1T5-T4-T3-T2-T1-REFREF-T1-T2-T3-T4-T5Total
Mean28.0 ± 2.633.0 ± 8.739.3 ± 10.332.0 ± 14.122.0 ± 2.637.3 ± 12.931.9 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (T) 1-T3-Reference (REF)-T5-T2-T4T2-REF-T4-T1-T5-T3T3-T5-T1-T4-REF-T2T4-T2-T5-REF-T3-T1T5-T4-T3-T2-T1-REFREF-T1-T2-T3-T4-T5Total
Female0000000
Male33333318
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Publications

  • Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME, Jungnik A, Gansser D, Ebner T, Muller F. Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):69-80. doi: 10.1007/s13318-017-0427-9. PubMed 28685495 ↗

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Dec 2015, 1 month.

Results were first posted in Feb 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2015
First posted
Oct 14, 2015
StartActual
Oct 12, 2015
Primary completionActual
Dec 9, 2015
CompletionActual
Dec 14, 2015
Results first posted
Feb 13, 2017
Last update
Nov 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02574845
Responsible party
Sponsor
First posted
Oct 14, 2015
Start date
Oct 12, 2015
Primary completion
Dec 9, 2015
Completion
Dec 14, 2015
Results posted
Feb 13, 2017
Last update
Nov 7, 2023

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Furosemide

Start the discussion